Senolytics, Gene Therapy and Lifestyle Can Slow Cardiovascular Aging
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
20 articles
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
A comprehensive review of in vitro assays for inducing cellular senescence and screening senolytic drugs, highlighting key challenges in clinical translation.
Fucoidan, dasatinib+quercetin, and MitoQ each counteract hyperoxia-driven cellular senescence in fetal airway cells via distinct mechanisms.
A new study pinpoints chemotherapy-induced senescent bone marrow cells as the culprit behind bone loss, and shows senolytics can prevent it.
A phase 1 trial of dasatinib + quercetin in 5 early AD patients uncovers fluid biomarker changes that could guide future senolytic trials.
4-month senolytic treatment with D+Q cleared senescent RPE cells, reduced lipofuscin, and preserved vision in a preclinical dry AMD model.
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
A novel anti-swelling hydrogel loaded with dasatinib, quercetin, and nucleus pulposus exosomes clears senescent cells and restores disc integrity in rats and goats.
Dasatinib and quercetin clear senescent cochlear cells, reducing inflammation and preserving hair cells in aging mice.
Comprehensive review identifies senolytics, NAD+ precursors, mTOR inhibitors and other compounds targeting aging hallmarks.
Dasatinib plus quercetin cleared senescent cells and reduced inflammation, improving alveolar bone health in aged mice.
Review reveals how anti-cancer drugs are being repurposed to eliminate senescent cells, opening new pathways for longevity treatments.
Alendronate-modified liposomes carrying dasatinib and quercetin doubled bone volume in chemotherapy-induced osteoporosis models.
New research reveals how aging liver cells release harmful vesicles that promote cancer metastasis across multiple tumor types.
Researchers develop BH3 profiling to predict senolytic drug effectiveness, moving beyond one-size-fits-all aging treatments.
Dasatinib and quercetin nanoparticles improve egg quality and fertility in aging mouse ovaries by clearing senescent cells.
New review reveals senolytic therapies can both help and harm cardiovascular health, challenging clinical translation.
Study shows senolytic combination therapy reduces cellular aging in gums and prevents periodontal bone loss in aging mice.